US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

  1. March 27, 2024

    NY AG, Others Blast Sandoz Deal 'Tax' On Future Settlements

    New York's attorney general was one of three objectors Tuesday to a provision in Sandoz's proposed $265 million settlement with a class of drug wholesalers in Pennsylvania federal court that they say will delay any future generic-drug price-fixing litigation deals by taxing agreements over $119.25 million.

  2. March 14, 2024

    Drug Wholesalers Want Preliminary OK On $265M Sandoz Deal

    A group of direct purchasers of generic drugs has asked a Pennsylvania federal court for approval of a $265 million settlement with Swiss drugmaker Sandoz over allegations of federal antitrust violations.

  3. February 29, 2024

    Sandoz To Pay $265M To Resolve Claims In Price-Fixing MDL

    Swiss generic drug and biosimilar manufacturer Sandoz announced Thursday that two of its subsidiaries have reached a $265 million settlement with the direct purchasers of generic medications to resolve allegations of federal antitrust violations.

  4. February 14, 2024

    Settlements of 3 Drug Cos. Get Prelim OK In Price-Fixing MDL

    A Pennsylvania federal judge granted preliminary approval Wednesday to settlements in which two makers and one distributor of generic drugs agreed to pay a combined $45 million to resolve allegations they colluded to fix the prices of medications, including those used to treat glaucoma, high blood pressure and high cholesterol.

  5. February 01, 2024

    State-Led Generic Drug Cases Removed From MDL

    The Judicial Panel on Multidistrict Litigation has sent a trio of cases from state-level enforcers back to federal court in Connecticut, separating them from the sprawling MDL centralized in Pennsylvania over claims of price fixing in the generic drug industry.

  6. January 23, 2024

    3 Generic-Drug Cos. Reach Settlements In Price-Fixing MDL

    Generic-drug makers Apotex Corp., Heritage Pharmaceuticals Ltd. and Breckenridge Pharmaceutical Inc. have each agreed to shell out a combined $45 million to settle allegations they colluded to fix the prices of many medications, according to a trio of motions filed Tuesday in multidistrict litigation in Pennsylvania federal court.

  7. January 17, 2024

    Generic-Drug Cos. Say States Are Mum In MDL Discovery

    Generic-drug makers steeped in antitrust multidistrict litigation are asking for an order enforcing a months-old deadline for documents that most states have ignored, according to a memorandum filed in Pennsylvania federal court.

  8. December 07, 2023

    Generics Price-Fixing Cases Should Stay In MDL, Judge Says

    The Pennsylvania federal judge overseeing sprawling multidistrict litigation against generic-drug makers on Thursday told the U.S. Judicial Panel on Multidistrict Litigation that she does not recommend transferring state enforcer actions out of the MDL yet, saying there's more the court can do to get the cases ready for trial or to tee up settlement talks.

  9. November 02, 2023

    States Want Generic Drug Price-Fixing Claims Back In Conn.

    State enforcers accusing several generic drugmakers of price-fixing asked the Judicial Panel on Multidistrict Litigation to move their case back to Connecticut federal court, saying legislation signed by President Joe Biden last year spares state enforcers from the MDL process.

  10. October 04, 2023

    States Back Off Bid To Block Sandoz Spinoff In Antitrust Case

    Novartis AG completed the planned spinoff of its Sandoz unit on Wednesday, after state enforcers and others withdrew their bid to block the move over concerns about recovering alleged overcharges from a sprawling conspiracy to fix generic drug prices.